Could a ketamine mist lift severe depression fast?
NCT ID NCT06752759
First seen May 02, 2026 · Last updated Jun 11, 2026 · Updated 10 times
Summary
This study tests whether inhaling ketamine through a nebulizer can quickly reduce symptoms of moderate to severe depression in hospitalized adults. About 40 participants will receive either ketamine or a placebo (midazolam) and be monitored for changes in depression scores over 8-10 days. The goal is to see if this approach offers a fast-acting treatment option for those in need.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL NERVOUS SYSTEM AGENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Maimonides Medical Center
RECRUITINGBrooklyn, New York, 11219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.